Impact of adjuvant immunotherapy on prognosis in esophageal squamous cell carcinoma patients following neoadjuvant immunochemotherapy

IntroductionThe CheckMate-577 trial confirmed that adjuvant nivolumab significantly prolonged disease-free survival (DFS) in patients with esophageal cancer who had residual disease after neoadjuvant chemoradiotherapy (nCRT). However, whether postoperative adjuvant immunotherapy (AIT) is necessary f...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jiayi Geng, Bengang Hui, Teng Mu, Ni Ping, Runmin Jiang, Xiuyuan Chen, Heng Zhao, Dan zeng duo ji, Xizhao Sui, Yun Li, Xun Wang, Jie Lei
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2026-03-01
Col·lecció:	Frontiers in Oncology
Matèries:	adjuvant therapy esophageal squamous cell carcinoma immunochemotherapy immunotherapy neoadjuvant therapy
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1735049/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!